LPHM LEE PHARMACEUTICALS
- 0.099000
- 0.0000000.00%
LEE PHARMACEUTICALS News
Earnings Miss: Gan & Lee Pharmaceuticals. Missed EPS By 30% And Analysts Are Revising Their Forecasts
As you might know, Gan & Lee Pharmaceuticals. (SHSE:603087) last week released its latest quarterly, and things did not turn out so great for shareholders. Unfortunately, Gan & Lee Pharmaceutical
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) shares have had a horrible month, losing 30% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year's worth
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
When you see that almost half of the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 8.4x, Gan & Lee Pharmaceuticals. (SHSE:603087) looks to be giving off stron
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug
Gan & Lee Pharmaceuticals (SHA:603087) administered the first subject for the Phase II clinical trial of its type 2 diabetes drug, GZR101. The trial, which was approved by China's National Medical Pro
Insiders Own 33% of Gan & Lee Pharmaceuticals. (SHSE:603087) Shares but Individual Investors Control 41% of the Company
Key Insights Significant control over Gan & Lee Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions A tota
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement
Gan & Lee Pharmaceuticals (SHA:603087) obtained approval from the China Securities Regulatory Commission to issue shares to specific investors. The Chinese pharmaceutical company is allowed to issue s
Shareholders in Gan & Lee Pharmaceuticals (SHSE:603087) Have Lost 12%, as Stock Drops 3.1% This Past Week
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Investors in Gan &
Gan & Lee Pharmaceuticals. (SHSE:603087) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Gan & Lee Pharmaceuticals' (SHSE:603087) stock increased significantly by 8.1% over the past month. But the company's key financial indicators appear to be d
RONN Motor Group Applies for a Name Change to RONN Inc.
Express News | RONN MOTOR GROUP, INC. APPLIES FOR A NAME CHANGE TO RONN INC. AS ITS REVERSE MERGER WITH FORMER LEE PHARMACEUTICALS HAS BEEN COMPLETED LPHM
Press Release: RONN Motor Group Announced the Merger and Takeover of LPHM Is Nearly Completed
RONN Motor Group Announced the Merger and Takeover of LPHM is Nearly Completed PR Newswire PHOENIX, Ariz., March 15, 2023 PHOENIX, Ariz., March 15, 2023 /PRNewswire/ -- Lee Pharmaceuticals (OTC: LP
Press Release: RONN Motor Group Announces the Addition of Corporate Global Strategist & Executive Vice President- Sheila Stewart, and Sonic Seven Communications, a Global PR & Marketing Firm
RONN Motor Group Announces the addition of Corporate Global Strategist & Executive Vice President- Sheila Stewart, and Sonic Seven Communications, a Global PR & Marketing Firm PR Newswire PHOENIX, M
Press Release: Lee Pharmaceuticals and RONN Motor Group, a Premier Zero-emission Hydrogen Electric Automotive Company, Have Signed a Definitive Reverse Merger Agreement
Lee Pharmaceuticals and RONN Motor Group, a premier zero-emission hydrogen electric automotive company, have signed a definitive reverse merger agreement PR Newswire MOBILE, Ala., Feb. 16, 2023 MOB
Gan & Lee Pharmaceuticals' (SHSE:603087) One-year Decline in Earnings Translates Into Losses for Shareholders
Gan & Lee Pharmaceuticals. (SHSE:603087) shareholders should be happy to see the share price up 13% in the last month. But in truth the last year hasn't been good for the share price. After all, t
Gan & Lee Pharmaceuticals.'s (SHSE:603087) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Gan & Lee Pharmaceuticals' (SHSE:603087) stock is up by 4.4% over the past week. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by long-term fund
Gan & Lee Pharmaceuticals' Insulin Injection Enters Pakistani Market
12:43 AM EST, 12/09/2022 (MT Newswires) -- Gan & Lee Pharmaceuticals' (SHA:603087) insulin glargine injection will be sold in Pakistan after securing the approval of the Drug Regulatory Authority of P
Gan & Lee Pharmaceuticals. (SHSE:603087) Top Key Executive Gan Zhongru's Holdings Dropped 4.3% in Value as a Result of the Recent Pullback
A look at the shareholders of Gan & Lee Pharmaceuticals. (SHSE:603087) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual insiders with
The One-year Loss for Gan & Lee Pharmaceuticals (SHSE:603087) Shareholders Likely Driven by Its Shrinking Earnings
Gan & Lee Pharmaceuticals. (SHSE:603087) shareholders should be happy to see the share price up 15% in the last week. But that's not enough to compensate for the decline over the last twelve mo
Are Gan & Lee Pharmaceuticals.'s (SHSE:603087) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at Gan & Lee Pharmaceuticals' (SHSE:603087) recent performance, when its stock has declined 18% over the past three months. It is possible that the market
Windtree Therapeutics in Global Licensing Agreement for KL4 Surfactant, Aerosurf
By Chris Wack Windtree Therapeutics Inc. said Tuesday it has entered into a global licensing agreement with Lee's Pharmaceutical Limited for the development and commercialization of Windtree's acute
Analysis
Price Target
No Data
